About the Event
The Hepatitis B Virus (HBV) infects 270 million people globally and complications caused by HBV kill close to 1 million people per year.
Given the scope and urgency of the problem, Assembly Bio (NASDAQ: ASMB) has several programs in its pipeline for curing HBV. A triple combo trial is currently in Phase 2 and an a novel oral core inhibitor drug will enter clinical trials this year.
Assembly Bio CEO, Dr. John McHutchison led the successful development of a cure for Hepatitis C. Joining him is a team with over 80 years of experience in treating HCV, HIV, and HBV. In addition to an experienced executive team, the company’s board of directors includes Nobel Laureate, Sir Michael Houghton, PhD.
Join this webinar to hear from the Dr. McHutchison as he discusses the company’s three-tiered strategic approach to curing HBV and the major inflection points that are coming this year and next.